Cargando…
The c-Abl inhibitor, Nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease
c-Abl is activated in the brain of Parkinson's disease (PD) patients and in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-intoxicated mice where it inhibits parkin through tyrosine phosphorylation leading to the accumulation of parkin substrates, and neuronal cell death. In the present st...
Autores principales: | Karuppagounder, Senthilkumar S., Brahmachari, Saurav, Lee, Yunjong, Dawson, Valina L., Dawson, Ted M., Ko, Han Seok |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4007078/ https://www.ncbi.nlm.nih.gov/pubmed/24786396 http://dx.doi.org/10.1038/srep04874 |
Ejemplares similares
-
c-Abl and Parkinson’s Disease: Mechanisms and Therapeutic Potential
por: Brahmachari, Saurav, et al.
Publicado: (2017) -
Parthanatos Mediates AIMP2 Activated Age Dependent Dopaminergic Neuronal Loss
por: Lee, Yunjong, et al.
Publicado: (2013) -
Synthetic mRNAs Drive Highly Efficient iPS Cell Differentiation to Dopaminergic Neurons
por: Xue, Yingchao, et al.
Publicado: (2018) -
Defects in Mitochondrial Biogenesis Drive Mitochondrial Alterations in PARKIN-Deficient Human Dopamine Neurons
por: Kumar, Manoj, et al.
Publicado: (2020) -
PARIS induced defects in mitochondrial biogenesis drive dopamine neuron loss under conditions of parkin or PINK1 deficiency
por: Pirooznia, Sheila K., et al.
Publicado: (2020)